Single User License
INR 136040
Site License
INR 272080
Corporate User License
INR 408120

Service Tax Additional

select a format
Price

Single User License
USD 2000
Site License
USD 4000
Corporate User License
USD 6000

Alternatively

Request a quote
Request a Customized research
Request for Sample Report





Recent Viewed Reports


Why Ken Reasearch?


Testimonials

While we still are studying and analysing your reports about Vietnam & Thailand, we would like to convey to your research team that they have done a very good job in compiling so much of information together. We hope to see more of such well researched reports. All the best & keep it up. ... "Prashant Bhagwat,General Manager, Mahindra"

We would like to appreciate Ken Research for their great efforts and wonderful support in providing the Market Intelligence Report for ITPC. The information, statistics and research are well understandable and very clear to the point. We are happy with Ken research for their good client service, on-time delivery of the report and as said the report itself. Thank you Ken research for bringing the valuable output for us. We would be looking forward to have more research with you in the near future. Wish you a success in your business!... "Jestin Mathew, Indonesian Trade Promotion Center"

The Report was very interesting and useful for me... "Marketing Manager, Western Union Business Solutions"

Ken Research completed the report successfully with tough deadline and large requirement. Really appreciate it... "Sales Manager, Largest India Aesthetic Laser Manufacturer"

We found the report really useful in understanding the complex Indian market and it provided lots of high quality insights. On the basis of this we commissioned Ken to produce a bespoke follow up to answer some specific questions about our market. This is now being used to help develop our marketing and sales strategy. We were very pleased with the comprehensive coverage, detail provided and actionable insights.... "Owner, Therefore Consulting UK"


Age Related Macular Degeneration-Pipeline Review, H1 2015

Age Related Macular Degeneration-Pipeline Review, H1 2015


  Request for Sample Report

Executive Summary

Age Related Macular Degeneration-Pipeline Review, H1 2015

Summary

Global Markets Direct's, 'Age Related Macular Degeneration-Pipeline Review, H1 2015', provides an overview of the Age Related Macular Degeneration's therapeutic pipeline.

This report provides comprehensive information on the therapeutic development for Age Related Macular Degeneration, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Age Related Macular Degeneration and special features on late-stage and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

The report provides a snapshot of the global therapeutic landscape of Age Related Macular Degeneration

The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities

The report reviews key players involved in the therapeutics development for Age Related Macular Degeneration and enlists all their major and minor projects

The report summarizes all the dormant and discontinued pipeline projects

A review of the Age Related Macular Degeneration products under development by companies and universities/research institutes based on information derived from company and industry-specific sources

Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages

A detailed assessment of monotherapy and combination therapy pipeline projects

Coverage of the Age Related Macular Degeneration pipeline on the basis of target, MoA, route of administration and molecule type

Latest news and deals relating related to pipeline products

Reasons To Buy

Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies

Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

Develop strategic initiatives by understanding the focus areas of leading companies

Identify and understand important and diverse types of therapeutics under development for Age Related Macular Degeneration

Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline

Devise corrective measures for pipeline projects by understanding Age Related Macular Degeneration pipeline depth and focus of Indication therapeutics

Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Table of Contents

Table of Contents 2

Introduction 7

Age Related Macular Degeneration Overview 8

Therapeutics Development 9

Age Related Macular Degeneration-Therapeutics under Development by Companies 11

Age Related Macular Degeneration-Therapeutics under Investigation by Universities/Institutes 22

Age Related Macular Degeneration-Pipeline Products Glance 25

Age Related Macular Degeneration-Products under Development by Companies 29

Age Related Macular Degeneration-Products under Investigation by Universities/Institutes 41

Age Related Macular Degeneration-Companies Involved in Therapeutics Development 43

Age Related Macular Degeneration-Therapeutics Assessment 152

Drug Profiles 168

Age Related Macular Degeneration-Recent Pipeline Updates 430

Age Related Macular Degeneration-Dormant Projects 545

Age Related Macular Degeneration-Discontinued Products 555

Age Related Macular Degeneration-Product Development Milestones 556

Appendix 566

List of Tables

Number of Products under Development for Age Related Macular Degeneration, H1 2015 30

Number of Products under Development for Age Related Macular Degeneration-Comparative Analysis, H1 2015 31

Number of Products under Development by Companies, H1 2015 33

Number of Products under Development by Companies, H1 2015 (Contd..1) 34

Number of Products under Development by Companies, H1 2015 (Contd..2) 35

Number of Products under Development by Companies, H1 2015 (Contd..3) 36

Number of Products under Development by Companies, H1 2015 (Contd..4) 37

Number of Products under Development by Companies, H1 2015 (Contd..5) 38

Number of Products under Development by Companies, H1 2015 (Contd..6) 39

Number of Products under Development by Companies, H1 2015 (Contd..7) 40

Number of Products under Development by Companies, H1 2015 (Contd..8) 41

Number of Products under Development by Companies, H1 2015 (Contd..9) 42

Number of Products under Investigation by Universities/Institutes, H1 2015 44

Number of Products under Investigation by Universities/Institutes, H1 2015 (Contd..1) 45

Comparative Analysis by Late Stage Development, H1 2015 46

Comparative Analysis by Clinical Stage Development, H1 2015 47

Comparative Analysis by Early Stage Development, H1 2015 48

Comparative Analysis by Unknown Stage Development, H1 2015 49

Products under Development by Companies, H1 2015 50

Products under Development by Companies, H1 2015 (Contd..1) 51

Products under Development by Companies, H1 2015 (Contd..2) 52

Products under Development by Companies, H1 2015 (Contd..3) 53

Products under Development by Companies, H1 2015 (Contd..4) 54

Products under Development by Companies, H1 2015 (Contd..5) 55

Products under Development by Companies, H1 2015 (Contd..6) 56

Products under Development by Companies, H1 2015 (Contd..7) 57

Products under Development by Companies, H1 2015 (Contd..8) 58

Products under Development by Companies, H1 2015 (Contd..9) 59

Products under Development by Companies, H1 2015 (Contd..10) 60

Products under Development by Companies, H1 2015 (Contd..11) 61

Products under Investigation by Universities/Institutes, H1 2015 62

Products under Investigation by Universities/Institutes, H1 2015 (Contd..1) 63

Age Related Macular Degeneration-Pipeline by Achillion Pharmaceuticals, Inc., H1 2015 64

Age Related Macular Degeneration-Pipeline by Acucela Inc., H1 2015 65

Age Related Macular Degeneration-Pipeline by Aerie Pharmaceuticals, Inc., H1 2015 66

Age Related Macular Degeneration-Pipeline by Aerpio Therapeutics, Inc., H1 2015 67

Age Related Macular Degeneration-Pipeline by Alexion Pharmaceuticals, Inc., H1 2015 68

Age Related Macular Degeneration-Pipeline by Alimera Sciences, Inc., H1 2015 69

Age Related Macular Degeneration-Pipeline by Alkeus Pharmaceuticals, Inc., H1 2015 70

Age Related Macular Degeneration-Pipeline by Allergan Plc, H1 2015 71

Age Related Macular Degeneration-Pipeline by Allergan, Inc., H1 2015 72

Age Related Macular Degeneration-Pipeline by Allinky Biopharma, H1 2015 73

Age Related Macular Degeneration-Pipeline by Amakem NV, H1 2015 74

Age Related Macular Degeneration-Pipeline by Amarna Therapeutics B.V., H1 2015 75

Age Related Macular Degeneration-Pipeline by Amyndas Pharmaceuticals LLC, H1 2015 76

Age Related Macular Degeneration-Pipeline by AngioGenex, Inc., H1 2015 77

Age Related Macular Degeneration-Pipeline by Angstrom Pharmaceuticals, Inc., H1 2015 78

Age Related Macular Degeneration-Pipeline by Apellis Pharmaceuticals, Inc., H1 2015 79

Age Related Macular Degeneration-Pipeline by Applied Genetic Technologies Corporation, H1 2015 80

Age Related Macular Degeneration-Pipeline by Aprogen, Inc., H1 2015 81

Age Related Macular Degeneration-Pipeline by Avalanche Biotechnologies, Inc., H1 2015 82

Age Related Macular Degeneration-Pipeline by Bayer AG, H1 2015 83

Age Related Macular Degeneration-Pipeline by Benitec Biopharma Limited, H1 2015 84

Age Related Macular Degeneration-Pipeline by BIOCAD, H1 2015 85

Age Related Macular Degeneration-Pipeline by Bioheart, Inc., H1 2015 86

Age Related Macular Degeneration-Pipeline by Biokine Therapeutics Ltd., H1 2015 87

Age Related Macular Degeneration-Pipeline by BioMAS Ltd., H1 2015 88

Age Related Macular Degeneration-Pipeline by Boehringer Ingelheim GmbH, H1 2015 89

Age Related Macular Degeneration-Pipeline by Caladrius Biosciences, Inc. , H1 2015 90

Age Related Macular Degeneration-Pipeline by Catalyst Biosciences, Inc., H1 2015 91

Age Related Macular Degeneration-Pipeline by Cell Cure Neurosciences, Ltd., H1 2015 92

Age Related Macular Degeneration-Pipeline by Charlesson LLC., H1 2015 93

Age Related Macular Degeneration-Pipeline by Circadian Technologies Limited, H1 2015 94

Age Related Macular Degeneration-Pipeline by Clanotech AB, H1 2015 95

Age Related Macular Degeneration-Pipeline by Clearside BioMedical, Inc., H1 2015 96

Age Related Macular Degeneration-Pipeline by Colby Pharmaceutical Company, H1 2015 97

Age Related Macular Degeneration-Pipeline by Crinetics Pharmaceuticals, Inc., H1 2015 98

Age Related Macular Degeneration-Pipeline by Critical Pharmaceuticals Limited, H1 2015 99

Age Related Macular Degeneration-Pipeline by Digna Biotech, S.L., H1 2015 100

Age Related Macular Degeneration-Pipeline by Dong-A Socio Group, H1 2015 101

Age Related Macular Degeneration-Pipeline by e-Therapeutics Plc, H1 2015 102

Age Related Macular Degeneration-Pipeline by Eleven Biotherapeutics Inc., H1 2015 103

Age Related Macular Degeneration-Pipeline by F. Hoffmann-La Roche Ltd., H1 2015 104

Age Related Macular Degeneration-Pipeline by Foamix Pharmaceuticals Ltd., H1 2015 105

Age Related Macular Degeneration-Pipeline by Gene Signal International SA, H1 2015 106

Age Related Macular Degeneration-Pipeline by Genentech, Inc., H1 2015 107

Age Related Macular Degeneration-Pipeline by GenSight Biologics SA, H1 2015 108

Age Related Macular Degeneration-Pipeline by GlaxoSmithKline Plc, H1 2015 109

Age Related Macular Degeneration-Pipeline by Grupo Ferrer Internacional, S.A., H1 2015 110

Age Related Macular Degeneration-Pipeline by GTx, Inc., H1 2015 111

Age Related Macular Degeneration-Pipeline by HanAll Biopharma Co., Ltd., H1 2015 112

Age Related Macular Degeneration-Pipeline by Huabo Biopharm Co., Ltd., H1 2015 113

Age Related Macular Degeneration-Pipeline by iCo Therapeutics Inc., H1 2015 114

Age Related Macular Degeneration-Pipeline by Icon Bioscience, Inc., H1 2015 115

Age Related Macular Degeneration-Pipeline by Iconic Therapeutics, Inc., H1 2015 116

Age Related Macular Degeneration-Pipeline by IMMD Inc., H1 2015 117

Age Related Macular Degeneration-Pipeline by Innovent Biologics, Inc., H1 2015 118

Age Related Macular Degeneration-Pipeline by Intellect Neurosciences, Inc., H1 2015 119

Age Related Macular Degeneration-Pipeline by International Stem Cell Corporation, H1 2015 120

Age Related Macular Degeneration-Pipeline by Jeil Pharmaceutical Co., Ltd., H1 2015 121

Age Related Macular Degeneration-Pipeline by Johnson & Johnson, H1 2015 122

Age Related Macular Degeneration-Pipeline by Juno Therapeutics Inc., H1 2015 123

Age Related Macular Degeneration-Pipeline by Kadmon Corporation, LLC, H1 2015 124

Age Related Macular Degeneration-Pipeline by Kala Pharmaceuticals, Inc., H1 2015 125

Age Related Macular Degeneration-Pipeline by Lead Discovery Center GmbH, H1 2015 126

Age Related Macular Degeneration-Pipeline by LeadArtis S.L., H1 2015 127

Age Related Macular Degeneration-Pipeline by Lpath, Inc., H1 2015 128

Age Related Macular Degeneration-Pipeline by Mabion SA, H1 2015 129

Age Related Macular Degeneration-Pipeline by MacuCLEAR, Inc., H1 2015 130

Age Related Macular Degeneration-Pipeline by Merz Pharma GmbH & Co. KgaA, H1 2015 131

Age Related Macular Degeneration-Pipeline by Mesoblast Limited, H1 2015 132

Age Related Macular Degeneration-Pipeline by Navigen Pharmaceuticals, Inc., H1 2015 133

Age Related Macular Degeneration-Pipeline by Neovacs SA, H1 2015 134

Age Related Macular Degeneration-Pipeline by Neumedicines Inc., H1 2015 135

Age Related Macular Degeneration-Pipeline by Neuroptis Biotech, H1 2015 136

Age Related Macular Degeneration-Pipeline by Neurotech Pharmaceuticals, Inc., H1 2015 137

Age Related Macular Degeneration-Pipeline by Novartis AG, H1 2015 138

Age Related Macular Degeneration-Pipeline by Ocata Therapeutics, Inc., H1 2015 139

Age Related Macular Degeneration-Pipeline by OcuCure Therapeutics, Inc., H1 2015 140

Age Related Macular Degeneration-Pipeline by Ocular Therapeutix, Inc., H1 2015 141

Age Related Macular Degeneration-Pipeline by Ohr Pharmaceutical Inc., H1 2015 142

Age Related Macular Degeneration-Pipeline by Omeros Corporation, H1 2015 143

Age Related Macular Degeneration-Pipeline by Ophthotech Corp., H1 2015 144

Age Related Macular Degeneration-Pipeline by Ora Bio Ltd., H1 2015 145

Age Related Macular Degeneration-Pipeline by Orphagen Pharmaceuticals, Inc., H1 2015 146

Age Related Macular Degeneration-Pipeline by Oxford BioMedica Plc, H1 2015 147

Age Related Macular Degeneration-Pipeline by PanOptica, Inc., H1 2015 148

Age Related Macular Degeneration-Pipeline by Pfenex Inc., H1 2015 149

Age Related Macular Degeneration-Pipeline by Pfizer Inc., H1 2015 150

Age Related Macular Degeneration-Pipeline by Promedior, Inc., H1 2015 151

Age Related Macular Degeneration-Pipeline by pSivida Corp., H1 2015 152

Age Related Macular Degeneration-Pipeline by QLT Inc., H1 2015 153

Age Related Macular Degeneration-Pipeline by Quark Pharmaceuticals, Inc., H1 2015 154

Age Related Macular Degeneration-Pipeline by R-Tech Ueno, Ltd., H1 2015 155

Age Related Macular Degeneration-Pipeline by Regeneron Pharmaceuticals, Inc., H1 2015 156

Age Related Macular Degeneration-Pipeline by Resolvyx Pharmaceuticals, Inc, H1 2015 157

Age Related Macular Degeneration-Pipeline by RestorGenex Corporation, H1 2015 158

Age Related Macular Degeneration-Pipeline by Santen Pharmaceutical Co., Ltd., H1 2015 159

Age Related Macular Degeneration-Pipeline by Sanwa Kagaku Kenkyusho Co., Ltd., H1 2015 160

Age Related Macular Degeneration-Pipeline by SciFluor Life Sciences, LLC, H1 2015 161

Age Related Macular Degeneration-Pipeline by Shionogi & Co., Ltd., H1 2015 162

Age Related Macular Degeneration-Pipeline by Sirnaomics, Inc., H1 2015 163

Age Related Macular Degeneration-Pipeline by StemCells, Inc., H1 2015 164

Age Related Macular Degeneration-Pipeline by Sumitomo Dainippon Pharma Co., Ltd., H1 2015 165

Age Related Macular Degeneration-Pipeline by Sun Pharma Advanced Research Company Ltd., H1 2015 166

Age Related Macular Degeneration-Pipeline by ThromboGenics NV, H1 2015 167

Age Related Macular Degeneration-Pipeline by TRACON Pharmaceuticals, Inc., H1 2015 168

Age Related Macular Degeneration-Pipeline by TWi Pharmaceuticals, Inc., H1 2015 169

Age Related Macular Degeneration-Pipeline by Varinel, Inc., H1 2015 170

Age Related Macular Degeneration-Pipeline by VasGene Therapeutics, Inc., H1 2015 171

Age Related Macular Degeneration-Pipeline by Wellstat Ophthalmics Corporation, H1 2015 172

Assessment by Monotherapy Products, H1 2015 173

Number of Products by Stage and Target, H1 2015 175

Number of Products by Stage and Mechanism of Action, H1 2015 181

Number of Products by Stage and Route of Administration, H1 2015 186

Number of Products by Stage and Molecule Type, H1 2015 188

Age Related Macular Degeneration Therapeutics-Recent Pipeline Updates, H1 2015 451

Age Related Macular Degeneration-Dormant Projects, H1 2015 566

Age Related Macular Degeneration-Dormant Projects (Contd..1), H1 2015 567

Age Related Macular Degeneration-Dormant Projects (Contd..2), H1 2015 568

Age Related Macular Degeneration-Dormant Projects (Contd..3), H1 2015 569

Age Related Macular Degeneration-Dormant Projects (Contd..4), H1 2015 570

Age Related Macular Degeneration-Dormant Projects (Contd..5), H1 2015 571

Age Related Macular Degeneration-Dormant Projects (Contd..6), H1 2015 572

Age Related Macular Degeneration-Dormant Projects (Contd..7), H1 2015 573

Age Related Macular Degeneration-Dormant Projects (Contd..8), H1 2015 574

Age Related Macular Degeneration-Dormant Projects (Contd..9), H1 2015 575

Age Related Macular Degeneration-Discontinued Products, H1 2015 576

List of Figures

Number of Products under Development for Age Related Macular Degeneration, H1 2015 30

Number of Products under Development for Age Related Macular Degeneration-Comparative Analysis, H1 2015 31

Number of Products under Development by Companies, H1 2015 32

Number of Products under Investigation by Universities/Institutes, H1 2015 43

Comparative Analysis by Late Stage Development, H1 2015 46

Comparative Analysis by Clinical Stage Development, H1 2015 47

Comparative Analysis by Early Stage Products, H1 2015 48

Assessment by Monotherapy Products, H1 2015 173

Number of Products by Top 10 Targets, H1 2015 174

Number of Products by Stage and Top 10 Targets, H1 2015 174

Number of Products by Top 10 Mechanism of Actions, H1 2015 180

Number of Products by Stage and Top 10 Mechanism of Actions, H1 2015 180

Number of Products by Top 10 Routes of Administration, H1 2015 185

Number of Products by Stage and Top 10 Routes of Administration, H1 2015 185

Number of Products by Top 10 Molecule Types, H1 2015 187

Number of Products by Stage and Top 10 Molecule Types, H1 2015 187

Single User License:
Report can be used by individual purchaser only

Site License:
Report can be shared by unlimited users within one corporate location, e.g. a regional office

Corporate User License:
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

To know more information on Purchase by Section, please send a mail to query [@] kenresearch.com
 

Achillion Pharmaceuticals, Inc.

Acucela Inc.

Aerie Pharmaceuticals, Inc.

Aerpio Therapeutics, Inc.

Alexion Pharmaceuticals, Inc.

Alimera Sciences, Inc.

Alkeus Pharmaceuticals, Inc.

Allergan Plc

Allergan, Inc.

Allinky Biopharma

Amakem NV

Amarna Therapeutics B.V.

Amyndas Pharmaceuticals LLC

AngioGenex, Inc.

Angstrom Pharmaceuticals, Inc.

Apellis Pharmaceuticals, Inc.

Applied Genetic Technologies Corporation

Aprogen, Inc.

Avalanche Biotechnologies, Inc.

Bayer AG

Benitec Biopharma Limited

BIOCAD

Bioheart, Inc.

Biokine Therapeutics Ltd.

BioMAS Ltd.

Boehringer Ingelheim GmbH

Caladrius Biosciences, Inc.

Catalyst Biosciences, Inc.

Cell Cure Neurosciences, Ltd.

Charlesson LLC.

Circadian Technologies Limited

Clanotech AB

Clearside BioMedical, Inc.

Colby Pharmaceutical Company

Crinetics Pharmaceuticals, Inc.

Critical Pharmaceuticals Limited

Digna Biotech, S.L.

Dong-A Socio Group

e-Therapeutics Plc

Eleven Biotherapeutics Inc.

F. Hoffmann-La Roche Ltd.

Foamix Pharmaceuticals Ltd.

Gene Signal International SA

Genentech, Inc.

GenSight Biologics SA

GlaxoSmithKline Plc

Grupo Ferrer Internacional, S.A.

GTx, Inc.

HanAll Biopharma Co., Ltd.

Huabo Biopharm Co., Ltd.

iCo Therapeutics Inc.

Icon Bioscience, Inc.

Iconic Therapeutics, Inc.

IMMD Inc.

Innovent Biologics, Inc.

Intellect Neurosciences, Inc.

International Stem Cell Corporation

Jeil Pharmaceutical Co., Ltd.

Johnson & Johnson

Juno Therapeutics Inc.

Kadmon Corporation, LLC

Kala Pharmaceuticals, Inc.

Lead Discovery Center GmbH

LeadArtis S.L.

Lpath, Inc.

Mabion SA

MacuCLEAR, Inc.

Merz Pharma GmbH & Co. KgaA

Mesoblast Limited

Navigen Pharmaceuticals, Inc.

Neovacs SA

Neumedicines Inc.

Neuroptis Biotech

Neurotech Pharmaceuticals, Inc.

Novartis AG

Ocata Therapeutics, Inc.

OcuCure Therapeutics, Inc.

Ocular Therapeutix, Inc.

Ohr Pharmaceutical Inc.

Omeros Corporation

Ophthotech Corp.

Ora Bio Ltd.

Orphagen Pharmaceuticals, Inc.

Oxford BioMedica Plc

PanOptica, Inc.

Pfenex Inc.

Pfizer Inc.

Promedior, Inc.

pSivida Corp.

QLT Inc.

Quark Pharmaceuticals, Inc.

R-Tech Ueno, Ltd.

Regeneron Pharmaceuticals, Inc.

Resolvyx Pharmaceuticals, Inc

RestorGenex Corporation

Santen Pharmaceutical Co., Ltd.

Sanwa Kagaku Kenkyusho Co., Ltd.

SciFluor Life Sciences, LLC

Shionogi & Co., Ltd.

Sirnaomics, Inc.

StemCells, Inc.

Sumitomo Dainippon Pharma Co., Ltd.

Sun Pharma Advanced Research Company Ltd.

ThromboGenics NV

TRACON Pharmaceuticals, Inc.

TWi Pharmaceuticals, Inc.

Varinel, Inc.

VasGene Therapeutics, Inc.

Wellstat Ophthalmics Corporation

Age Related Macular Degeneration Therapeutic Products under Development, Key Players in Age Related Macular Degeneration Therapeutics, Age Related Macular Degeneration Pipeline Overview, Age Related Macular Degeneration Pipeline, Age Related Macular Degeneration Pipeline Assessment


Related Products in vertical
Other reports by publisher
Ken Research Pvt. Ltd. 27A, Tower B-2, Spaze I Tech Business Park, Sohna Road, sector 49
     Gurgaon, Haryana - 122001, India
+91 1244230204

download

Company Brochure

Engage with Us

query [@] kenresearch.com